Conexus LLC v. eSentire Inc. — Injection Exploit Detection Patent Dismissed With Prejudice
Conexus LLC filed a patent infringement action in the Eastern District of Texas against cybersecurity firm eSentire Inc., asserting US11736499B2 covering systems and methods for detecting injection exploits. The case closed 161 days after filing when Conexus voluntarily dismissed all claims with prejudice — before eSentire had filed any answer.
Cybersecurity patent suit ends before eSentire files a single pleading
On 2 December 2024, Conexus LLC filed suit against eSentire Inc. in the Eastern District of Texas (Judge Rodney Gilstrap, Case No. 2:24-cv-00986), asserting infringement of US11736499B2. That patent covers systems and methods for detecting injection exploits — a core cybersecurity capability directly relevant to eSentire’s managed detection and response business. Plaintiff was represented by Rabicoff Law LLC, a firm with a recognised presence in patent assertion litigation.
On 12 May 2025, Conexus filed a Notice of Voluntary Dismissal with prejudice under Federal Rule of Civil Procedure 41(a)(1)(A)(i). Because eSentire had not yet filed an answer or moved for summary judgment, Conexus was entitled to dismiss unilaterally without court consent. Judge Gilstrap accepted and acknowledged the dismissal, extinguishing all asserted claims. Critically, the dismissal was entered with prejudice, meaning Conexus is permanently barred from reasserting the same claims against eSentire. Each party was ordered to bear its own costs.
The 161-day duration — ending before the defendant engaged on the merits — is consistent with patterns seen in pre-answer settlement or licensing resolutions, though the public record does not confirm any such agreement. The with-prejudice designation is notable: plaintiffs typically seek without-prejudice dismissals to preserve optionality, so its use here suggests either a negotiated resolution or a considered decision to abandon this assertion. What drove Conexus to that endpoint remains undisclosed.
Filing to Voluntary dismissal in 161 days
161 days — resolved before defendant answered, well short of the typical E.D. Texas discovery schedule
Dismissed with prejudice: what the Rule 41 exit means for both sides
Rule 41(a)(1)(A)(i): unilateral dismissal before answer
Under FRCP 41(a)(1)(A)(i), a plaintiff may dismiss an action without court order if the defendant has not yet served an answer or a summary judgment motion. Conexus exercised that right, but chose to attach a with-prejudice designation — making the dismissal a final adjudication on the merits as a matter of law. The court’s role was limited to accepting and acknowledging the notice; no substantive ruling was made.
Voluntary, pre-answer exitWith prejudice means Conexus cannot refile against eSentire
A dismissal with prejudice operates as a final judgment on the merits, permanently barring the plaintiff from reasserting the same claims against the same defendant. A dismissal without prejudice would preserve the right to refile. Here, the notice expressly states ‘with prejudice.’ The public record does not disclose why Conexus elected this more restrictive exit — whether by agreement with eSentire, in exchange for a licence, or for other strategic reasons — leaving that question open.
Claims permanently extinguishedeSentire exits without conceding infringement or validity
eSentire never filed an answer, meaning it made no formal admissions and no court ever ruled on infringement or the validity of US11736499B2. The dismissal with prejudice protects eSentire from this specific assertion, but the patent itself remains granted and enforceable against others. eSentire’s freedom-to-operate posture on injection exploit detection technology should be assessed independently of this dismissal.
No merits adjudicationNo fee-shifting: each party absorbs its own costs
Judge Gilstrap ordered each party to bear its own costs, expenses, and attorneys’ fees. This is the standard outcome in voluntary pre-answer dismissals and does not reflect a finding of exceptional case status under 35 U.S.C. § 285. Had eSentire sought fee recovery under § 285, it would have needed to demonstrate the case was objectively baseless — a high bar the court was never asked to reach here.
No § 285 fee awardFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Conexus LLC | Company | Patent assertion entity — holder of US11736499B2 covering injection exploit detectionSearch in Eureka ↗ |
| Defendant | eSentire Inc. | Company | eSentire Inc. — managed detection and response (MDR) cybersecurity services providerSearch in Eureka ↗ |
| Plaintiff counsel | Isaac Phillip Rabicoff | Attorney | Counsel for Conexus LLCSearch in Eureka ↗ |
| Plaintiff law firm | Rabicoff Law LLC | Law Firm | Representing Conexus LLCSearch in Eureka ↗ |
| Presiding judge | Judge Rodney Gilstrap | Judge | Texas Eastern District CourtSearch in Eureka ↗ |
Official order — verbatim text
The court’s order accepts and acknowledges the voluntary dismissal with prejudice filed by Conexus under Rule 41(a)(1)(A)(i). No finding of infringement, invalidity, or non-infringement was made. The phrase ‘dismissed with prejudice’ carries full claim-preclusive effect for Conexus against eSentire, but confers no precedential weight on the merits of US11736499B2. The each-party-bears-own-costs directive forecloses any post-dismissal fee motion by eSentire under 35 U.S.C. § 285.
US11736499B2 — Systems and Methods for Detecting Injection Exploits
US11736499B2, filed under application number US16/844915, protects systems and methods for detecting injection exploits — a category of cyberattack that includes SQL injection, command injection, and related techniques used to compromise application and network security. The patent’s technical scope places it squarely within the managed detection and response (MDR) and security operations centre (SOC) technology domain, where real-time threat identification is a core product differentiator.
For cybersecurity vendors, this patent represents a meaningful assertion risk. Injection exploit detection is not a peripheral feature — it sits at the core of endpoint, network, and application security platforms offered by MDR providers, SIEMs, and next-generation firewall vendors. With Conexus having demonstrated willingness to file in E.D. Texas before Judge Gilstrap, and with the patent surviving this litigation intact, other players in the detection and response market should assess their exposure to this claim set before receiving a complaint.
Should you run an FTO analysis against US11736499B2?
Any vendor building or commercialising systems that detect injection-based attacks — whether at the network, application, or endpoint layer — should consider a freedom-to-operate review against US11736499B2. This includes MDR providers, SIEM platform vendors, web application firewall developers, and cloud-native security services companies. The patent survived the Conexus v. eSentire litigation without any validity challenge reaching the court, meaning its claims remain untested and potentially enforceable.
PatSnap Eureka’s FTO Search Agent enables R&D and IP teams to map the claim language of US11736499B2 against existing product architectures, identify relevant prior art, and benchmark against the broader injection exploit detection patent landscape. Proactive FTO analysis — before a complaint arrives — is materially cheaper than responding to an E.D. Texas assertion under Judge Gilstrap, where case scheduling pressure is well documented.
Run a freedom-to-operate analysis on US11736499B2 to assess your product’s exposure
Run FTO in Eureka →Similar cybersecurity patent infringement cases in E.D. Texas
Explore related patent infringement actions involving cybersecurity and threat detection technology litigated in the Eastern District of Texas.
What this case signals for the cybersecurity patent enforcement landscape
Pre-answer dismissals with prejudice in E.D. Texas are a recurring signal worth tracking for cybersecurity IP teams.
With-prejudice exit suggests the assertion reached a conclusion — not a retreat
Plaintiffs asserting nuisance-value claims typically dismiss without prejudice to preserve leverage elsewhere. The with-prejudice designation here suggests Conexus either secured what it sought — potentially a licence or settlement — or made a deliberate strategic decision to close this chapter. Either reading signals a more substantive resolution than a simple case drop.
US11736499B2 remains live against the broader MDR market
The dismissal resolves only the dispute with eSentire. US11736499B2 has not been invalidated, and Conexus retains the right to assert it against other managed detection and response providers. Competitors operating in the injection exploit detection space should treat this patent as an active enforcement risk and consider FTO analysis.
Conexus v eSentire — key questions answered
Conexus LLC sued eSentire Inc. in the Eastern District of Texas for infringement of US11736499B2, covering systems and methods for detecting injection exploits. On 12 May 2025, Conexus voluntarily dismissed the case with prejudice under FRCP 41(a)(1)(A)(i) before eSentire filed any answer. Each party bore its own costs.
Dismissal with prejudice operates as a final judgment on the merits, permanently barring Conexus from reasserting the same claims against eSentire. Conexus retains the patent and may assert it against other defendants, but eSentire specifically is protected from this assertion going forward.
No. The court made no ruling on infringement or the validity of US11736499B2. The case was dismissed before eSentire answered, meaning no merits adjudication occurred. The patent remains granted and enforceable. Its validity and infringement scope were never tested in this litigation.
US11736499B2, filed as US16/844915, covers systems and methods for detecting injection exploits — including attack types such as SQL injection and command injection. The patent is relevant to managed detection and response platforms, SIEMs, web application firewalls, and other cybersecurity products that identify and block injection-based attacks in real time.
The public record does not disclose the reason. However, plaintiffs who expect to refile typically dismiss without prejudice to preserve that option. A with-prejudice exit suggests Conexus either reached a private resolution — such as a licence or settlement — or made a deliberate decision to abandon the assertion against eSentire specifically. Neither scenario is confirmed by the available court documents.
PatSnap Eureka searches patents and litigation data to answer instantly.